NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2004 (Six months ended)
Business Overview: NAI develops, manufactures, markets, and distributes nutritional supplements. The company operates primarily in the United States and Europe, with a focus on private label contract manufacturing and a direct-to-consumer marketing program.

Key Financial Metrics

Note: Debt figures derived from Balance Sheet (Current portion of long-term debt + Long-term debt less current portion + other term loans disclosed in notes).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 31% year-over-year, driven by a 41% increase in private label contract manufacturing sales. Direct-to-consumer sales declined 25% due to reduced media spending.
• Margin Compression: Gross profit margin decreased to 22.4% from 23.7%. This was primarily caused by a shift in sales mix toward higher-volume, lower-margin products, increasing material costs as a percentage of sales by 4.0 percentage points.
• Profitability: Despite margin compression, Net Income increased 43% to $1.637 million. This was aided by a 332% increase in "Other income, net," largely due to foreign exchange gains ($166,000) and a gain on the sale of a previously written-off investment.
• Capital Expenditures: Investing cash outflows surged to $5.238 million (from $1.443 million) to fund the build-out of a 46,000 sq. ft. facility in Vista, California, completed in January 2005.
• Operating Expenses: SG&A expenses increased 11% in absolute dollars but decreased as a percentage of sales (17.2% vs 20.2%) due to revenue leverage. Increases were driven by Sarbanes-Oxley compliance ($210,000) and R&D initiatives ($932,000).

Guidance, Outlook, and Risks

• Outlook: Management expects relatively steady net sales for the remainder of fiscal 2005. Profitability is expected to remain positive but at reduced levels due to higher regulatory costs and facility transition expenses.
• Strategic Focus: The company plans to discontinue relationships with two newer private label customers to focus on larger, higher-quality clients. Negotiations to renew the manufacturing agreement with its largest customer (NSA International, Inc.) began in January 2005.
• Regulatory Costs: The company incurred $392,000 in regulatory costs related to the Therapeutic Goods Administration (TGA) of Australia certification review. These costs are expected to continue.
• Tax Implications: A five-year Swiss tax holiday for the European subsidiary (NAIE) expires June 30, 2005. Post-expiration, the effective tax rate for NAIE is expected to rise from ~5% to ~23%.
• Customer Concentration Risk: Two customers accounted for 76% of net sales for the six-month period. The loss of either would have a material adverse impact.
• Foreign Exchange Risk: A 10% adverse change in exchange rates (Swiss Franc/Euro vs. USD) would have decreased net income by $348,000 for the period.

Investor Verification Checklist

• Customer Renewal: Verify the status of the manufacturing agreement renewal with NSA International, Inc., which represents a significant portion of revenue.
• Facility Transition: Monitor the operational ramp-up of the new Vista, California facility to ensure no disruption in manufacturing capabilities.
• Tax Rate Impact: Assess the financial impact of the expiration of the Swiss tax holiday on June 30, 2005, and the resulting increase in effective tax rates.
• Regulatory Compliance: Track the outcome of the TGA certification review and associated ongoing costs.
• Direct-to-Consumer Strategy: Evaluate the effectiveness of the upgraded television programming and new direct mail initiatives planned for the third and fourth quarters of fiscal 2005.